Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China

Objective: This study examined the use, demographic and clinical correlates of antipsychotic polypharmacy (APP) and its associations with treatment satisfaction and quality of life (QOL) in schizophrenia patients in China. Method: A total of 4239 patients in 45 nationwide Chinese psychiatric hospita...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Australian and New Zealand journal of psychiatry 2015-02, Vol.49 (2), p.129-136
Hauptverfasser: Li, Qian, Xiang, Yu-Tao, Su, Yun-Ai, Shu, Liang, Yu, Xin, Chiu, Helen FK, Correll, Christoph U, Ungvari, Gabor S, Lai, Kelly YC, Ma, Cui, Wang, Gao-Hua, Bai, Pei-Shen, Li, Tao, Sun, Li-Zhong, Shi, Jian-Guo, Chen, Xian-Sheng, Mei, Qi-Yi, Li, Ke-Qing, Si, Tian-Mei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: This study examined the use, demographic and clinical correlates of antipsychotic polypharmacy (APP) and its associations with treatment satisfaction and quality of life (QOL) in schizophrenia patients in China. Method: A total of 4239 patients in 45 nationwide Chinese psychiatric hospitals/centers were interviewed in 2012 in the third cross-sectional study, with the first two having been conducted in 2002 and 2006. Patients’ socio-demographic and clinical characteristics, including psychopathology, side effects, satisfaction with treatment and QOL, were recorded using a standardized protocol and data collection procedure. Results: The proportion of APP prescriptions in 2012 was 34.2%, which was significantly higher than the frequency of APP in 2002 (26.1%) and 2006 (26.4%) (p
ISSN:0004-8674
1440-1614
DOI:10.1177/0004867414536931